172 related articles for article (PubMed ID: 19863693)
1. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.
Schrötzlmair F; Kopitz C; Halbgewachs B; Lu F; Algül H; Brünner N; Gänsbacher B; Krüger A
J Cell Mol Med; 2010 Dec; 14(12):2760-70. PubMed ID: 19863693
[TBL] [Abstract][Full Text] [Related]
2. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1α.
Schelter F; Halbgewachs B; Bäumler P; Neu C; Görlach A; Schrötzlmair F; Krüger A
Clin Exp Metastasis; 2011 Feb; 28(2):91-9. PubMed ID: 21053058
[TBL] [Abstract][Full Text] [Related]
3. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling.
Kopitz C; Gerg M; Bandapalli OR; Ister D; Pennington CJ; Hauser S; Flechsig C; Krell HW; Antolovic D; Brew K; Nagase H; Stangl M; von Weyhern CW; Brücher BL; Brand K; Coussens LM; Edwards DR; Krüger A
Cancer Res; 2007 Sep; 67(18):8615-23. PubMed ID: 17875701
[TBL] [Abstract][Full Text] [Related]
4. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
Nalbandian A; Djakiew D
Clin Exp Metastasis; 2006; 23(2):107-16. PubMed ID: 16912916
[TBL] [Abstract][Full Text] [Related]
5. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Castelló R; Estellés A; Vázquez C; Falcó C; España F; Almenar SM; Fuster C; Aznar J
Clin Chem; 2002 Aug; 48(8):1288-95. PubMed ID: 12142386
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.
Schelter F; Grandl M; Seubert B; Schaten S; Hauser S; Gerg M; Boccaccio C; Comoglio P; Krüger A
Clin Exp Metastasis; 2011 Dec; 28(8):793-802. PubMed ID: 21789719
[TBL] [Abstract][Full Text] [Related]
7. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
Lee KH; Choi EY; Hyun MS; Jang BI; Kim TN; Lee HJ; Eun JY; Kim HG; Yoon SS; Lee DS; Kim JH; Kim JR
Clin Exp Metastasis; 2008; 25(1):89-96. PubMed ID: 17992475
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver.
Kopitz C; Gerg M; Gansbacher B; Krüger A
Hum Gene Ther; 2008 Oct; 19(10):1039-49. PubMed ID: 18681831
[TBL] [Abstract][Full Text] [Related]
9. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
[TBL] [Abstract][Full Text] [Related]
10. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration.
Sisson TH; Nguyen MH; Yu B; Novak ML; Simon RH; Koh TJ
Blood; 2009 Dec; 114(24):5052-61. PubMed ID: 19812386
[TBL] [Abstract][Full Text] [Related]
12. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
14. Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis.
Endo-Munoz L; Cai N; Cumming A; Macklin R; Merida de Long L; Topkas E; Mukhopadhyay P; Hill M; Saunders NA
PLoS One; 2015; 10(8):e0133592. PubMed ID: 26317203
[TBL] [Abstract][Full Text] [Related]
15. Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
Shi C; Zhang N; Feng Y; Cao J; Chen X; Liu B
Cell Physiol Biochem; 2017; 41(4):1313-1324. PubMed ID: 28278500
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis.
Shimizu M; Hara A; Okuno M; Matsuno H; Okada K; Ueshima S; Matsuo O; Niwa M; Akita K; Yamada Y; Yoshimi N; Uematsu T; Kojima S; Friedman SL; Moriwaki H; Mori H
Hepatology; 2001 Mar; 33(3):569-76. PubMed ID: 11230736
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer.
Lee KH; Choi EY; Hyun MS; Jang BI; Kim TN; Kim SW; Song SK; Kim JH; Kim JR
Korean J Intern Med; 2006 Mar; 21(1):20-7. PubMed ID: 16646560
[TBL] [Abstract][Full Text] [Related]
18. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells.
Moriyama T; Kataoka H; Hamasuna R; Yoshida E; Sameshima T; Iseda T; Yokogami K; Nakano S; Koono M; Wakisaka S
Clin Exp Metastasis; 1999; 17(10):873-9. PubMed ID: 11089886
[TBL] [Abstract][Full Text] [Related]
20. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
Emenaker NJ; Basson MD
J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
